Dr. Greenbaum collaborates with industry partners to test new T1D therapeutics. These collaborations often involve multi-site phase 2 and phase 3 randomized clinical trials with the goal of understanding the efficacy of new therapies. A few of these collaborations include:
- Golimumab: Completed phase 2 multi-site randomized “TIGER” trial that demonstrated golimumab can preserve insulin secretion after diagnosis
- Teplizumab: Completed phase 3 multi-site randomized “PROTECT” trial, results expected in 2023
